Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cellular Therapy

Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients

Bone Marrow Transplantation volume 50, pages 51–55 (2015)Cite this article

Subjects

Abstract

The aim of this study was to analyse the experience of Polish Pediatric Group for Hematopoietic Stem Cell Transplantation in respect to donor lymphocyte infusion procedure. The study included 51 pediatric patients with malignant (45) and non-malignant (6) diseases treated with DLI in the period 1993–2012. The indications for DLI were as follows: (1) increasing recipient chimerism after non-ablative hematopoietic SCT (18 patients); (2) immunomodulation after a reduced intensity conditioning regimen (2 patients); (3) increase in minimal residual disease detection (3 patients); and (4) relapse (28 patients). DLI was carried out at a median of 6 (0.5–79) months after SCT. DLI was administered as either a single-dose (in 19 cases) or in escalating-dose regimens (in 32 cases). The median total dose of CD3-positive T cells was 28.0 (0.1–730.0) × 106/kg body weight. The time for assessment of DLI efficacy ranged from 0 to 70 (median 3) months. At evaluation, 18 patients experienced CR, 3 achieved PR, 19 showed relapse and 11 rejected the graft. DLI was found to be effective in 39% of cases. Complications of the procedure occurred in 18 patients; of these, 2 died. To sum up DLI shows efficacy in a significant percentage of children. Mortality related to the therapy adverse effects is low. However, this method requires standardization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553–1562.

    CAS  PubMed  Google Scholar 

  2. Deol A, Lum LG Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation. Cancer Treat Rev 2010; 36: 528–538.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Introna M, Barbui AM, Golay J, Rambaldi A Innovative cell-based therapies in onco-hematology: what are the clinical facts? Haematologica 2004; 89: 1253–1260.

    PubMed  Google Scholar 

  4. Porter DL, Antin JH Donor leukocyte infusions in myeloid malignancies: new strategies. Best Practice Res Clin Haematol 2006; 19: 737–755.

    Article  CAS  Google Scholar 

  5. Imamura M, Tanaka J Graft-versus-leukemia effect of non-myeloablative stem cell transplantation. Korean J Intern Med 2009; 24: 287–298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sprangers B, Van Wijmeersch B, Fevery S, Wear M, Billiau AD Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol 2007; 4: 404–414.

    Article  PubMed  Google Scholar 

  7. Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423–1431.

    Article  CAS  PubMed  Google Scholar 

  8. Resnick IB, Shapira MY, Slavin S Non-myeloablative stem cell transplantation and cell therapy for malignant and non-malignant disease. Transplant Immunol 2005; 14: 207–219.

    Article  CAS  Google Scholar 

  9. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 3: 5675–5687.

    Article  Google Scholar 

  10. Frey NV, Porter DL Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008; 21: 205–222.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Verholen F, Stalder M, Helg C, Chalandon Y Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 2004; 73: 441–446.

    Article  CAS  PubMed  Google Scholar 

  12. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925–935.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chiang LT, Yao M, Ko BS, Chen CH Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. Infection 2011; 39: 363–365.

    Article  CAS  PubMed  Google Scholar 

  14. Kawakami M, Nakata J, Ohguro N, Yoshihara S, Inoue T, Tatekawa T et al. A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis. Eur J Haematol 2005; 75: 352–354.

    Article  PubMed  Google Scholar 

  15. Kishi Y, Kami M, Oki Y, Kazuyama Y, Kawabata M . Donor lymphocyte infusion for treatment of life-threatening respiratory syncytial virus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26: 573–576.

    Article  CAS  PubMed  Google Scholar 

  16. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestation of graft versus host disease in human recipients of marrow from HLA matched sibling donor. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  17. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–956.

    Article  PubMed  Google Scholar 

  18. Simula MP, Marktel S, Fozza C, Keada J, Szydlo RM, Nadal E et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia 2007; 21: 943–948.

    Article  CAS  PubMed  Google Scholar 

  19. Blaira A, Gouldenb NJ, Libria NA, Oakhill A, Pamphilion DH Immunotherapeutic strategies in acute lymphoblastic leukemia relapsing after stem cell transplantation. Blood Rev 2005; 19: 289–300.

    Article  Google Scholar 

  20. Loren AW, Porter DL Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483–493.

    Article  CAS  PubMed  Google Scholar 

  21. Soiffer RJ Donor lymphocyte infusions for acute myeloid leukemia. Best Pract Res Clin Haematol 2008; 21: 455–466.

    Article  CAS  PubMed  Google Scholar 

  22. Suttorp M, Eckardt L, Tauer JT, Millot F Management of chronic myeloid leukemia in childhood. Curr Hematol Malig Rep 2012; 7: 116–124.

    Article  PubMed  Google Scholar 

  23. Oyekunle A, Klyuchnikov E, Ocheni S, Kroger N, Zander AR, Baccarani M et al. Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2011; 126: 30–39.

    Article  CAS  PubMed  Google Scholar 

  24. Klingebiel T, Bader P, EBMT Paediatric Working Party. Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant 2008; 41 (Suppl 2): 23–26.

    Article  Google Scholar 

  25. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119: 3256–3262.

    Article  CAS  PubMed  Google Scholar 

  26. Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y et al. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion 2014; 54: 1493–1500.

    Article  CAS  PubMed  Google Scholar 

  27. Levine JE, Barrett AJ, Zhang M-J, Arora M, Pulsipher MA, Bunin N et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008; 42: 201–205.

    Article  CAS  PubMed  Google Scholar 

  28. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1706.

    Article  PubMed  Google Scholar 

  29. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079–2086.

    Article  CAS  PubMed  Google Scholar 

  30. Rettinger E, Willasch AM, Kreyenberg H, Borkhardt A, Holter W, Kremens B et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011; 118: 5681–5688.

    Article  CAS  PubMed  Google Scholar 

  31. Rujkijyanont P, Morris C, Kang G, Gan K, Hartford C, Triplett B et al. Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia. Blood Cancer J 2013; 3: e137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Immunology and Transplantation, Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland

    J Gozdzik & A Krasowska-Kwiecien

  2. Department of Transplantation, Children’s University Hospital in Krakow, Krakow, Poland

    J Gozdzik, A Krasowska-Kwiecien & M Wozniak

  3. Department and Clinic of Bone Marrow Transplantation, Pediatrics Oncology and Hematology, Medical University in Wroclaw, Wroclaw, Poland

    K Rewucka, J Krukowska-Jaros, E Gorczynska, K Kalwak & A Chybicka

  4. Department and Clinic of Pediatrics Oncology, Hematology and Transplantation, Medical University in Poznan, Poznan, Poland

    A Pieczonka & J Wachowiak

  5. Department of Pediatrics, Hematology and Oncology, Nicolaus Copernicus University, Medical College in Bydgoszcz, Bydgoszcz, Poland

    R Debski & M Wysocki

  6. Department of Pediatric Hematology, Oncology and Transplantology, Medical University in Lublin, Lublin, Poland

    A Zaucha-Prazmo, K Drabko & J Kowalczyk

Authors
  1. J Gozdzik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Rewucka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Krasowska-Kwiecien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Pieczonka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Debski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Zaucha-Prazmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Drabko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Krukowska-Jaros
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Wozniak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Kowalczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Wysocki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Gorczynska
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. K Kalwak
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Chybicka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J Wachowiak
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation (PPGHSCT)

Corresponding author

Correspondence to J Gozdzik.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gozdzik, J., Rewucka, K., Krasowska-Kwiecien, A. et al. Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients. Bone Marrow Transplant 50, 51–55 (2015). https://doi.org/10.1038/bmt.2014.200

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.200

This article is cited by

Search

Advanced search

Quick links